Everolimus and Exemestane Combination Prolonged PFS for Advanced Postmenopausal Breast Cancer Patients

TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in In the News

For women with advanced breast cancer resistant to hormonal therapy, combining everolimus and exemestane improves progression-free survival (PFS) by nearly 7 months compared with exemestane alone, according to phase 3 trial results reported at the European Multi - disciplinary Cancer Conference. The Breast Cancer Trials of Oral Everolimus (BOLERO) randomized 724 patients in 24 countries who had been treated previously with letrozole or anastrozole. Previous therapy also included tamoxifen, fulvestrant, and chemotherapy. The trial was stopped early when interim analysis revealed that patients receiving the combination regimen did not experience tumor progression for nearly 11 months, whereas patients receiving exemestane alone progress after approximately 4 months.

Related Items
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Web Exclusives published on March 22, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Web Exclusives published on March 15, 2019 in FDA Approvals, News & Updates, In the News
March 08, 2019 – FDA Approvals, News & Updates
Web Exclusives published on March 8, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Pembrolizumab for Treatment of Advanced Melanoma
Web Exclusives published on February 22, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma
Web Exclusives published on February 19, 2019 in FDA Approvals, News & Updates, In the News
February 8, 2019 - FDA Approvals, News & Updates
Web Exclusives published on February 1, 2019 in FDA Approvals, News & Updates, In the News
February 1, 2019 - FDA Approvals, News & Updates
Web Exclusives published on February 1, 2019 in FDA Approvals, News & Updates, In the News
Government Shutdown Impacts FDA Drug Approvals
Web Exclusives published on January 14, 2019 in FDA Approvals, News & Updates, In the News
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
Web Exclusives published on February 15, 2017 in Conference Correspondent, In the News
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Web Exclusives published on February 15, 2017 in Conference Correspondent, In the News
Last modified: May 21, 2015